OptimizeRx (OPRX) Equity Average: 2011-2025
Historic Equity Average for OptimizeRx (OPRX) over the last 15 years, with Q3 2025 value amounting to $120.8 million.
- OptimizeRx's Equity Average rose 257.6% to $120.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $120.8 million, marking a year-over-year increase of 257.6%. This contributed to the annual value of $121.8 million for FY2024, which is 360.68% down from last year.
- According to the latest figures from Q3 2025, OptimizeRx's Equity Average is $120.8 million, which was up 257.6% from $117.8 million recorded in Q2 2025.
- OptimizeRx's Equity Average's 5-year high stood at $135.9 million during Q2 2022, with a 5-year trough of $85.9 million in Q1 2021.
- Moreover, its 5-year median value for Equity Average was $121.8 million (2024), whereas its average is $121.7 million.
- In the last 5 years, OptimizeRx's Equity Average skyrocketed by 18292.89% in 2021 and then plummeted by 1422.68% in 2023.
- Quarter analysis of 5 years shows OptimizeRx's Equity Average stood at $129.1 million in 2021, then decreased by 0.97% to $127.8 million in 2022, then fell by 5.09% to $121.3 million in 2023, then fell by 4.61% to $115.7 million in 2024, then increased by 4.36% to $120.8 million in 2025.
- Its Equity Average stands at $120.8 million for Q3 2025, versus $117.8 million for Q2 2025 and $116.6 million for Q1 2025.